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Background: Intestinal epithelial cells express 
genes for nutrient absorption. 
Results: Expression of the nutrient transporters 
is suppressed in the crypt and promoted in the 
villus by opposing transcription factors, changes 
of DNA methylation and histone modification.   
Conclusion: Gene expression in enterocytes is 
regulated by three different mechanisms. 
Significance: Removal of repressive 
transcriptional control elements is required to 
express enterocyte specific genes in the villus. 
 
ABSTRACT 
Enterocytes are specialized to absorb 
nutrients from the lumen of the small 
intestine by expressing a select set of genes to 
maximize the uptake of nutrients. They 
develop from stem cells in the crypt and 
differentiate into mature enterocytes while 
moving along the crypt-villus axis. Using, as 
an example, the Slc6a19 gene, encoding the 
neutral amino acid transporter B0AT1, we 
studied regulation of the gene by 
transcription factors and epigenetic factors in 
the intestine. To investigate this question we 
used a fractionation method to separate 
mature enterocytes from crypt cells and 
analysed gene expression. Transcription 
factors HNF1a and HNF4a activate 
transcription of the Slc6a19 gene in villus 
enterocytes, while high levels of SOX9 repress 
expression in the crypts. CpG dinucleotides in 
the proximal promoter were highly 
methylated in the crypt and fully de-
methylated in the villus. Furthermore, histone 
modification H3K27Ac, indicating an active 
promoter, was prevalent in villus cells but 
barely detectable in crypt cells. The results 
suggest that Slc6a19 expression in the 
intestine is regulated at three different levels 
involving promoter methylation, histone 
modification and opposing transcription 
factors.  
 
The small intestine is a highly 
specialized organ for nutrient digestion and 
absorption. Its anatomical structure is adapted to 
these tasks, including a highly differentiated 
crypt-villus structure forming a large surface to 
maximize uptake of digested nutrients. All 
epithelial cells originate from stem cells within 
the crypt, resulting in differentiated cell types for 
mucus production (Goblet cells), hormone 
production (enteroendocrine cells), host defense 
(Paneth cells), and absorption (enterocytes) (1). 
Enterocytes make up over 80% of all intestinal 
epithelial cells. They are highly polarized, 
possessing a brush border structure at their 
apical side, across which nutrients are absorbed 
(1). Therefore, the differentiation of crypt stem 
cells into fully differentiated absorptive 
enterocytes located in the villi of the small 
intestine is an excellent model for studying the 
transcriptional control mechanisms of protein 
sets that are required for nutrient absorption.  
At the enterocyte brush-border of the 
small intestine, peptides resulting from protein 
digestion by pancreatic proteases are further 1  
hydrolysed into individual amino acids, as well 
as di- and tripeptides (2). The majority of neutral 
amino acids are taken up through an active 
transport process involving the neutral amino 
acid transporter B0AT1 (encoded by the Slc6a19 
gene, throughout the manuscript we will use 
Slc6a19 when referring to the gene and B0AT1 
to identify the protein). The B0AT1 transporter is 
a Na+-amino acid symporter, and is located in 
the apical membrane of the absorptive 
enterocytes (3). Apart from being expressed in 
the small intestine, it is also detected in the 
apical membrane of proximal kidney tubule 
cells, and to a smaller degree in the pancreas (4) 
and the skin, but is not detected in any other 
tissue. B0AT1 requires auxiliary proteins for 
expression at the cell surface, namely collectrin 
(TMEM27) in the kidney (5,6), and ACE2 
(Angiotensin-Converting Enzyme 2) in the small 
intestine (7). For enterocytes to transport neutral 
amino acids, it is thus necessary to express both 
ACE2 and B0AT1 simultaneously. Due to its 
activity as a carboxypeptidase, ACE2 contributes 
to peptide digestion and feeds, together with 
aminopeptidase N, amino acids to the B0AT1 
transporter (8).  
The Hepatocyte Nuclear Factors HNF1a, 
HNF1b and HNF4a are part of an autoregulatory 
transcriptional network in mammalian pancreas, 
liver, kidney and gut (9). HNF1a and HNF1b are 
homeobox-containing transcriptional activators. 
HNF1a was first identified as a tissue-specific 
regulator of liver function (10), but has been 
shown to be expressed across a small number of 
tissues, including kidney, pancreas, and 
intestine. Mutations in the DNA-binding domain 
of HNF1a are the cause of type 3 maturity-onset 
diabetes of the young (MODY3), which is 
characterized by progressive loss of insulin 
secretory capacity (11). HNF1a is assumed to act 
as a master regulator for the transcription of 
transporters in the kidney, because HNF1a 
deficient mice manifest a general defect in the 
renal re-absorption of metabolites (12). 
Additionally, most of the renal amino-acid 
transporters in murines contain HNF1a-binding 
motifs within their proximal promoter regions 
(13). While HNF1a is expressed in three 
different isoforms in humans, rodents only 
express a single isoform, most likely resulting in 
species-specific regulatory differences (9). The 
absence of epithelial amino acid transporter 
expression in the liver despite HNF1a 
expression, has been suggested to be due to 
DNA methylation, thus preventing the 
interaction of HNF1a with the transport 
promoter binding sites (13). However, the 
observed DNA methylation was at a significant 
distance from the proximal promoter. 
Genome-wide expression profiling 
carried out with liver tissue of HNF1a deficient 
mice showed that HNF1a is involved in the 
regulation of several important hepatic functions, 
such as bile acid and cholesterol metabolism 
(14). A comparative study with liver and 
pancreatic island tissue revealed that HNF1a-
dependent genes encode a broad range of 
metabolic functions in both tissues, including 
those for amino acid transport and steroid, lipid, 
and xenobiotic metabolism (15). Pancreatic 
tissue of HNF1a deficient mice exhibits down-
regulation of the non-epithelial amino acid 
transporter SLC38A4, ACE2, collectrin, and the 
Nuclear factor HNF4a (15,16). In liver HNF4a 
appears to control expression of Hnf1a, while the 
opposite is observed in pancreas due to the use 
of an alternate Hnf4a promoter, which is 
controlled by HNF1a (16). Both promoters are 
used in the duodenum. HNF1b is a paralogue of 
HNF1a with indistinguishable in vitro DNA-
binding properties (17). HNF1b is highly 
expressed in pancreatic islets, yet only expressed 
at low levels in adult liver (15). Interestingly, 
HNF1b expression has been shown to be 
increased in HNF1a-/- liver tissue (15). 
Mutations in HNF1b are the principal cause for 
the MODY5 phenotype, exhibiting atrophy in 
the pancreas as well as several forms of renal 
disease (18). 
HNF4a is a highly conserved, zinc-
finger containing transcriptional activator of the 
steroid hormone nuclear receptor superfamily. In 
contrast to most nuclear receptors however, 
HNF4a does not appear to be activated by 
exogenous ligands (19). HNF4a is expressed at 
high levels in liver, kidney, small intestine, 
colon, and pancreatic beta cells. Loss-of-
function mutations in HNF4a result in MODY1, 
a monogenic autosomal dominant non-insulin-
dependent diabetes mellitus type II phenotype, 
exhibiting a decrease in glucose-induced insulin 
release (20). As mentioned above HNF4a 
controls the transcription of the Hnf1a gene in 
liver (16), thus indirectly regulating a vast array 
of genes vital for hepatocyte function (21). It 
was reported previously that HNF1a can down-
regulate HNF4a-mediated activation of 
transcription via a direct interaction of these 
transcription factors (22). In contrast, others 
observed that HNF4a enhances the 2  
transcriptional activity of HNF1a independent of 
its DNA-binding activity, possibly through 
recruitment of other co-activating regulators 
(23). HNF4a appears to play an important role 
early in embryonic development, as indicated by 
its presence as a maternal component of the egg, 
and its expression in mouse embryonic stem 
cells (24). During development, HNF4a 
expression precedes the expression of HNF1a 
and HNF1b, implying that HNF4a is a 
transcription factor higher up in the hierarchy of 
regulatory proteins, thus establishing the 
importance of HNF4a for proper terminal 
differentiation of hepatocytes (24). 
HNF1a and HNF1b appear to play 
important roles in terminal differentiation and 
cell fate commitment in the intestine, 
particularly for the Paneth cell lineage. HNF1b is 
expressed throughout development from the 
primitive gut stage through organogenesis, while 
HNF1a is expressed later during organogenesis 
(25). HNF4a has been suggested to be a major 
transcriptional regulator in the intestine. 
Genome-wide ChIP-chip analysis in the human 
Caco-2 cell line indicates that HNF4a is 
associated with regulatory regions of over a 
thousand genes (26). While these included some 
genes involved in digestion and absorption, 
many key proteins were missing, such as the 
glucose transporter SGLT1, the cationic amino 
acid transporter rbat/b0,+AT, sucrose/isomaltase, 
B0AT1, ACE2 etc.  The analysis revealed 
transcription factor networks, in which HNF4a 
regulates the expression of CDX2. A model has 
been proposed in which HNF4a initiates the 
differentiation-dependent transcription by 
activating Hnf1a and Cdx2, both encoding 
transcription factors which are required 
simultaneously for the expression of many genes 
specifically expressed in the intestine (26,27). 
In order to shed light onto the regulatory 
mechanisms responsible for the co-expression of 
ACE2 and B0AT1 in enterocytes of the small 
intestine, we have enriched  crypt stem cells and 
absorptive villi enterocytes using a modified 
Traber method (28), and subjected them to a 
genome-wide expression analysis, combined 
with a bioinformatics approach to identify 
transcription factor candidates for the regulation 
of ACE2 and B0AT1 expression. The 
involvement of candidate genes was then 
investigated utilizing both in vitro and in vivo 
methods, namely reporter gene assays and 
Chromatin Immunoprecipitation (ChIP).  
 
Experimental Procedures 
 
Molecular cloning and DNA manipulation 
All primer pairs used in this study are 
listed in Supplementary Table 1 and were 
purchased from Sigma-Aldrich. The Slc6a19 
promoter region was amplified by nested PCR 
using genomic DNA from mouse kidney. 
Initially a fragment ranging from position -2639 
to position +374 was amplified by standard PCR 
using Pfu polymerase. This fragment was used 
as a template for a second PCR, which used 
primers with an incorporated KpnI and BglII site 
spanning from position -2494 to +57. The 
product of this reaction was cut with KpnI and 
BglII and inserted into the reporter gene vector 
pGL4.12 (Promega). The Ace2 promoter was 
cloned using a similar strategy. Initially an 
1856bp fragment was amplified from genomic 
DNA (position -1602 to +254). This fragment 
was used as a template for a second PCR, which 
used primers with an incorporated XhoI and 
KpnI site spanning from position -1509 to +170. 
The product of this reaction was cut with XhoI 
and KpnI and inserted into the reporter gene 
vector pGL4.12 (Promega). Promoter deletions 
were made using the full promoter construct in 
pGL4.12 by inverse PCR. Reverse and forward 
primers flanking the desired deletion were used 
to amplify the complete vector minus the 
deletion and the resulting fragment was re-
ligated. To clone transcription factors, mRNA 
was isolated from mouse intestine (RNeasy plus, 
Qiagen) and converted into cDNA using 
Superscript II reverse transcriptase (Invitrogen). 
Sox9 cDNA was cloned by nested PCR. Initially 
a larger fragment was amplified, followed by 
amplification of the coding sequence with 
primers containing a BamHI (sense) and a EcoRI 
(antisense) site. The fragment was digested with 
both enzymes and ligated into pcDNA3.1(+) 
(Invitrogen). Hnf1a cDNA was purchased from 
Thermo Scientific (clone ID:30471380), the 
cDNA being inserted into pCMV-SPORT. 
Hnf4a cDNA was amplified from intestinal 
cDNA using primers incorporating BamHI and 
EcoRI cutting sites. After digestion, the cDNA 
was ligated into the corresponding cites of 
pcDNA3.1(+).  
Putative transcription factor binding 
sites in the reporter-gene constructs were 
verified by site-directed mutagenesis using the 
Quikchange II site directed mutagenesis kit 
(Agilent). Primers for the mutagenesis were 
designed using the manufacturer’s 3  
recommendations. All constructs were 
confirmed by sequencing. 
 
In situ hybridization 
 Tissue specimens of small intestine from 
C57BL/6, SWR/J and DBA1/J mice were fixed in 
4% paraformaldehyde/0.1 M sodium phosphate 
buffer (pH 7.2) for 4 hours and embedded in 
paraffin. Five µm tissue sections were de-waxed 
and hybridized as previously described (29). 
Hybridization probes were generated by in vitro 
transcription of mB0AT1 cDNA cloned into pCR-
blunt II-TOPO using SP6 polymerase (antisense) 
and T7 polymerase (sense). The hybridization 
mixture (10 mM Tris HCl, pH 7.4, 50% (vol/vol) 
deionized formamide, 600 mM NaCl, 1 mM 
EDTA, 0.02% polyvinylpyrrolidone, 0.02% 
Ficoll, 0.05% bovine serum albumin, 10% 
dextrane sulfate, 10 mM dithiothreitol, 200 µg/ml 
denatured sonicated salmon sperm DNA, 100 
µg/ml rabbit liver tRNA) contained either the 35S-
labeled RNA antisense or sense control mB0AT1 
probe at a concentration of 500 ng/ml. 
Hybridization with RNA probes proceeded at 
42ºC for 18 hr. Following washing steps, the slide 
preparations were dipped in NTB2 emulsion 
(Kodak) and exposed at 4°C for 3 weeks. After 
development the slides were stained with 
hematoxylin/eosin and photographed with a Sony 
DSC digital camera. 
 
Cell fractionation of mouse intestine 
A fractionation method was used to 
isolate cell populations enriched with crypt and 
villus cells. This method is based on the inverted 
intestinal sac method first described by Barnard 
et al. (30) and further optimized by Traber et al. 
(28).  In brief, the small intestine was cut after 
the duodenum and before the ileocaecal 
boundary and flushed with PBS containing 1 
mM DTT. Subsequently, 6 cm long sections of 
mouse jejunum were inverted onto a plastic rod. 
The plastic rod was inserted into a hole in the lid 
of a 12 ml plastic round-bottom centrifuge tube, 
containing 10 ml citrate buffer (96 mM NaCl, 
1.5 mM KCl, 27 mM Na3Citrate, 8 mM KH2PO4 
and 5.6 mM Na2HPO4, pH 7.4). After sealing, 
the assembly was incubated on a rotatory shaker 
at 37°C for 10 min. Subsequently, the citrate 
buffer was changed to 10 ml PBS containing 
0.5mM DTT, 1.5mM EDTA and 1mg/ml bovine 
serum albumin at 37°C. Rotary shaking was 
continued for 10-20 min until the solution was 
opaque indicating detachment of cells. The 
solution was exchanged against warm (37°C) 
fresh solution until 5-7 fractions were collected. 
Cell viability was judged by trypan blue 
exclusion.    
 
RNA isolation and microarray studies 
RNA was isolated from intestinal cell 
fractions using RNeasy (Qiagen). RNA quality 
was measured on a bioanalyser chip. Gene 
expression was analysed using an Agilent 
SurePrint G3 Mouse Exon Microarray through 
the Ramaciotti Center at the University of New 
South Wales. Expression levels of selected 
mRNA’s were confirmed by qPCR. 
 
Quantitative PCR (qPCR) 
Quantitative PCR was conducted using 
Fast SYBR Green master mix (Applied 
Biosystems) with the PCR being performed on 
an Applied Biosystems 7900 instrument. The 
reaction mixture (10 μl) included 5 μl SYBR 
Green master mix, 3 μl of sample cDNA (1:10 
dilution) and 1 μl of each primer (Concentration, 
200 nM). Subsequently, the mixture was pipetted 
into a 394-well plate. The PCR parameters were 
50°C for 2 min, 95°C for 15 s and 60°C for 1 
min running a total of 40 cycles. All samples 
were analysed in duplicate and experiments were 
repeated 3 times. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as an 
internal control. Primers were designed using 
Primer3 program (http://frodo.wi.mit.edu/) to 
amplify fragments of 170-250 bp.  
 
Bioinformatic promoter analysis 
The Slc6a19 promoter region ranging 
from -2494 to +57 was analysed using the 
University of California, Santa Cruz (UCSC) 
genome browser (http://genome.ucsc.edu). 
Bioinformatic analysis revealed that a region 
located between -228 bp +57 bp of the 
transcriptional start site (TSS) was highly 
conserved among different species (data not 
shown). A region of about 2.5 kb upstream of 
the TSS was analysed using the Genomatix 
MatInspector (genomatix.de) program. Relevant 
transcription factors in the Slc6a19 promoter 
region are listed in Table 1. 
 
Luciferase Assay (reporter gene assay) 
Reporter gene experiments were 
performed using the Dual-Luciferase Reporter 
Assay System (Promega). HEK293 cells (1x105 
cells per well) were seeded into 24-well plates 
24 hours prior to transfection using RPMI with 
5% fetal bovine calf serum (Invitrogen) at 37°C 4  
in 5% CO2 incubator. Transfections were 
performed with Lipofectamine LTX 
(Invitrogen). Cells were co-transfected with 
500ng of different Slc6a19 promoter constructs 
which were inserted into the pGL4.12[luc2CP] 
Vector (Promega), a total of 100 ng of 
transcription factor encoding plasmids (in 
pcDNA3.1) and 5 ng of pGL4.74[hRluc/TK] 
control vector (Promega). Luciferase activity 
was measured 24 hours after transfection using a 
Turner TD-20/20 luminometer according to the 
manufacturer’s instructions. 
 
Chromatin Immunoprecipitation Assay 
Chromatin Immunoprecipitation (ChIP) 
was performed as per the instructions of the 
SimpleChIP Enzymatic Chromatin IP Kit (Cell 
Signaling). Briefly, for each 
immunoprecipitation, 25mg of fresh or snap-
frozen mouse tissue was minced with a scalpel 
and placed in 1ml PBS containing protease 
inhibitors. Proteins and DNA were then cross-
linked with 1.5% formaldehyde (prepared fresh) 
for 20 minutes at room temperature. The reaction 
was stopped by the addition of a 1/10 of the 
volume of glycine stop-solution (10x). After a 5 
minute incubation the tissue was centrifuged for 
5 minutes at 1500 rpm at 4°C and then washed 
once with 1ml PBS containing protease 
inhibitors. After disaggregating the tissue with a 
potter homogenizer using 20-25 strokes, the cell 
suspension was centrifuged for 5 minutes at 4°C 
at 1500 rpm. The supernatant was immediately 
removed from the cells and nuclei were prepared 
as per the instructions of the kit. Chromatin was 
digested with Micrococcal Nuclease provided 
with the kit. This was followed by sonication of 
the sample twice, 2 min each, at 80% amplitude 
with a 15 second pulse on and 15 second pulse 
off time using a Misonix S4000 sonicator. 
Lysates were clarified by centrifugation at 10000 
rpm for 10 minutes at 4°C. The supernatant 
containing the cross-linked chromatin 
preparation was incubated overnight in 1-5 µg of 
the specific antibody. Samples were purified 
according to the instructions of the kit and 
analysed using qPCR. Antibodies were 
purchased from Abcam: H3K27ac(ab4729), 
H3K4me3(ab8580), SOX9(ab3697), 
HNF4a(ab41898), Cell signaling: IgG(#2729), 
H3(#4620), and Santa Cruz: HNF1a(sc-6547X)  
 
DNA Methylation/Bisulfite Sequencing 
Intestinal villus and crypt enterocytes 
were isolated using the fractionation protocol 
described above; other tissues were used after 
dissection. Following tissue extraction, genomic 
DNA was isolated using DNeasy Blood & 
Tissue kit (Qiagen). Isolated genomic DNA was 
treated with an EpiTect Bisulfite kit (Qiagen) 
according to the manufacturer’s instructions. In 
this process, all unmethylated cytosines are 
converted to uracil nucleotides, whereas all 
methylated cytosines (5-methylcytosine) remain 
intact during the treatment. The promoter region 
was amplified by nested PCR from bisulfite-
treated DNA. In the first round a 1639 bp 
fragment -1380 to +259 was amplified followed 
by amplification of a fragment ranging from -
1131 to +18. The PCR products were sequenced 
and analysed for the methylation status of all 
CpG dinucleotides in the target region.  
 
Results 
 
At the protein and mRNA level, B0AT1 is 
highly expressed in the villi, but absent in the 
crypt compartment. 
In confirmation of previous results (7), 
B0AT1 protein expression in the intestine shows 
a distinct gradient from the villus tip to the crypt 
(Fig. 1A). Expression is absent in the crypt and 
maximal in mature enterocytes at the villus tip. 
In situ hybridization confirms that this gradient 
is also observed at the level of mRNA (Fig. 1B). 
This is a typical feature of proteins involved in 
nutrient absorption and digestion, including 
angiotensin-converting enzyme 2 (data not 
shown), which is required for expression of 
B0AT1 at the cell surface. In order to understand 
the mechanisms of Slc6a19 transcriptional 
control, we analysed its promoter region. The 
proximal promoter of the mouse Slc6a19 gene, 
as judged by conservation of the sequence across 
mammalian species, appeared to be relatively 
short, i.e. 150 bp long. It is a typical class II 
promoter, where the transcriptional start site is 
preceded by a TATA binding motif (31) at 
position -23 to -28 and a reasonably conserved 
transcription factor IIB recognition motif (-39 to 
-46), indicating the binding site of general 
transcription factors and of polymerase II (31). 
The transcriptional start site CCACTT is similar 
to the mammalian consensus initiator sequence 
(31). Relevant transcription factor binding sites 
and their position are listed in Table 1.  
 
To investigate the tissue and cell specific 
expression of B0AT1, we generated reporter 
gene constructs using a 2kb fragment to account 5  
for possible species-specific regulatory elements 
that might be located outside the proximal 
promoter. When transfected into several 
different cell lines we could not detect 
significant reporter gene activity, suggesting that 
the promoter does not use common transcription 
factors found in a variety of cell lines. HNF1a 
and HNF4a (26), have been implicated as central 
players in the differentiation-induced expression 
of epithelial cells. When transfected into 
HEK293 cells, both transcription factors were 
sufficient to initiate transcription from the 
Slc6a19 promoter construct, with HNF4a being a 
stronger activator than HNF1a (Fig. 2A,B). 
Combined transfection of HNF1a and HNF4a 
did not increase reporter gene activity further 
(data not shown). The Ace2 promoter, by 
contrast, could be activated in vitro by HNF1a 
only (Fig. 2C). To identify the DNA binding 
sites for HNF1a and HNF4a, we generated 
promoter truncations and mutated predicted 
binding sites (Fig. 2). We identified two 
potential binding sites for HNF1a in the Slc6a19 
promoter located within 150 bp of the 
transcriptional start site (-126/-110 and -153/-
137). Site-directed mutagenesis was performed, 
indicating that the more distal site was not used, 
while an active binding site was identified at 
position -111/-114 (Fig. 2A). Mutation of this 
binding site abolished the observed 
transcriptional activation by HNF1a. A more 
distal site at position -1205/-1189 did not 
contribute to activation of the promoter (Fig. 
2A). Using the same constructs, it appeared that 
HNF4a had two functional binding sites, one 
located between -972 and -1378 and another 
within 136 bp of the transcriptional start site 
(Fig. 2B). Mutation of the predicted HNF4a 
binding site (-38/-41) that is proximal to the 
transcriptional start site abolished all reporter 
gene activity, indicating that this site is essential 
for recruitment of general transcription factors. 
Mutation of the predicted distal site (-1368/-
1344) did not change the response of the reporter 
construct to co-transfection of HNF4a (Fig. 2B). 
Further sequence analysis and mutagenesis of 
potential binding sites at position -1108/-1105 
and -1088/-1085 did not reveal an obvious 
HNF4a binding site between -972 to -1387. Thus 
the reason for the significant drop of HNF4a 
dependent reporter gene response after 
truncation of this region remains unclear. These 
results nevertheless demonstrate that HNF1a and 
HNF4a are both necessary and sufficient to 
initiate B0AT1 transcription in the background of 
HEK293 cells.      
 
Expression of transcription factors in crypt and 
villus enriched mouse small intestine cell 
fractions. 
Given the strong activation of B0AT1 
transcription by both HNF4a and HNF1a, a 
feasible mechanism to establish the B0AT1 
expression pattern along the villus-crypt axis 
would be by way of a villus-specific expression 
of these key regulators. To test this hypothesis 
we used a fractionation method to isolate cell 
populations along villus-crypt axis. The method 
showed strong enrichment of Slc6a19 mRNA at 
the villus tip fraction (ratio villus tip/crypt = 
~20-fold, Fig. 3A) and of the well-established 
intestinal stem cell marker Lgr5 (leucine-rich 
repeat containing G-protein coupled receptor 5) 
in the crypt-enriched fraction (ratio crypt/villus 
tip about 100-fold, Fig. 3B). This provided the 
basis for a genome-wide transcriptome 
comparison by microarray analysis. We analysed 
the crypt/villus ratio of all transcription factors 
that had significant expression in either crypts or 
villus tip (Table 1 listing those which have 
putative binding sites in the Slc6a19 promoter). 
Surprisingly, we found that Hnf1a and Hnf4a 
mRNAs were expressed in both villus and crypts 
at similar levels. Hnf4a mRNA was more 
abundant than Hnf1a mRNA. Expression levels 
of both mRNAs were confirmed by qPCR (data 
not shown). Moreover, CDX2 and GATA4, both 
being previously implicated in enterocyte-
specific expression (26,27,32), were either 
enriched in the crypt or expressed evenly (Table 
1). Thus expression of Slc6a19 mRNA in villus 
cells cannot be explained by a corresponding 
expression of Hnf1a, Hnf4a, Cdx2 or Gata4. A 
genome-wide survey showed that only eight 
transcription factors had robust expression and 
were significantly higher expressed in the villus 
than in the crypt (ratio > 3, Creb3l3, Stat3, Mafb, 
Tbx3, Max, Fosl2, Foxo6, Trp63). Only two of 
those (Creb3l3, Stat3) had putative binding sites 
in the Slc6a19 promoter. Co-transfection of 
Stat3 failed to activate reporter gene expression 
from the Slc6a19 promoter, even when activated 
by addition of IL-6 (Table 1 showing qualitative 
data for all transcription factors). Similarly, 
Creb3l3 failed to activate transcription when co-
transfected (Table 1). We therefore considered 
negative regulation to explain B0AT1 
expression. The mRNA of transcription factor 
Sox9 was highly expressed in the crypt, but 6  
barely found at the villus tip fraction (Fig. 3C 
and Table 1). Co-expression of SOX9 
suppressed Slc6a19 promoter activity, regardless 
whether it was driven by HNF1a (Fig. 4A) or 
HNF4a (Fig. 4B). Suppression of reporter gene 
activity was observed in all but the two shortest 
constructs, suggesting that the Slc6a19 core 
promoter contains a functional binding site for 
SOX9. Moreover, it also suppressed Ace2 
promoter activity driven by HNF1a (Fig. 2C), 
indicating that SOX9 may act in crypts as a 
general repressor of genes involved in intestinal 
nutrient absorption. A putative SOX9 binding 
site was identified at position -34/-37, 
overlapping with the HNF4a binding site. 
However, mutation of this binding site did not 
reduce SOX9 inhibition (data not shown). 
Further inspection of the proximal promoter 
revealed another putative SOX9 binding site at 
position -218/-215. Mutation of this site 
increased overall promoter activity and partially 
abrogated the SOX9 effect regardless whether 
transcription was driven by HNF1a (Fig. 5A) or 
HNF4a (Fig. 5B). Additional sequence analysis 
suggested a possible SOX9 binding sites a 
position +9/+12, mutation of which did not alter 
promoter activity. To investigate whether some 
of the SOX9 effect was independent of DNA 
binding, we co-transfected cells with the SOX9 
mutants H65Y, which is unable to bind DNA 
(33). Expression of this mutant still partially 
inhibited transcriptional activity, suggesting that 
SOX9 can act both as a sequence-specific 
transcription factor and as an inhibitory cofactor. 
When SOX9(H65Y) was co-transfected with a 
promoter containing the mutated SOX9 binding 
site, transcription was no longer inhibited by 
SOX9 (Fig. 5A,B).     
 
HNF1a, HNF4a and SOX9 bind to the B0AT1 
promoter in vivo.  
Transfection and overexpression of 
transcription factors in cell lines provides a first 
clue as to whether a potential binding site exists 
within a regulatory region, however, it does not 
provide evidence for in situ occupation of this 
binding site within the environment of a 
differentiated tissue. To investigate which of the 
transcription factor candidates identified in the 
reporter studies interact with the Slc6a19 
promoter in vivo, we performed ChIP assays 
using freshly scraped mucosa (Fig. 6). In 
agreement with the reporter gene studies we 
found binding of both HNF1a and HNF4a in the 
first 300bp upstream of the transcriptional start 
site. An additional binding site for HNF1a was 
found between -984 and -812, which was not 
observed in the reporter gene assays. No specific 
second binding site of HNF4a was observed 
consistent with mutagenesis studies of the 
putative distal binding site. Binding of SOX9 
was also detected in the proximal promoter, 
demonstrating that it can suppress transcription 
in situ (Fig. 6).   
 
Epigenetic elements affecting tissue expression 
To investigate whether epigenetic 
factors could contribute to the onset of B0AT1 
expression along the crypt-villus axis we 
compared villus and crypt fractions (Fig. 7A,B). 
Histone modification H3K4me3, indicating open 
promoter regions, was found both in the crypt 
and villus fractions. However, H3K27ac, also 
indicating active promoter regions, was highly 
abundant in the villus fraction, but barely 
detectable in the crypts. Liver cells showed a 
similar profile as crypts confirming that lack of 
H3K27ac is associated with lack of transcription 
(Fig. 7C). DNA methylation at CpG 
dinucleotides is widely known to be involved in 
gene silencing. Interestingly, it appears that CpG 
dinucleotides in the promoter region of Slc6a19 
are highly methylated in the crypt and become 
demethylated in the villus (Fig. 8). The Slc6a19 
promoter was also highly methylated in the liver, 
where B0AT1 is not expressed. The changes of 
methylation were particularly apparent around 
the proximal promoter where HNF1a and 
HNF4a and polymerase II bind. 
 
Discussion 
Here we present a model for the 
regulation of expression of proteins relevant for 
nutrient absorption in mature differentiated 
enterocytes. The model involves expression of 
an activating transcription factor in both crypt 
and villus compartment, which is counteracted 
by a transcriptional repressor whose expression 
is high in the crypt and low in the villus. The 
main activators are either HNF4a and to a lesser 
extent HNF1a, whilst SOX9, which shows 
maximum expression levels around the crypt, 
appears to play the role of a transcriptional 
repressor.  
Genome-wide screens of HNF 
transcription factor targets have been performed 
for both pancreas and liver (34), and for HNF4a 
in intestinal cells (26). However, these datasets 
have not revealed how enterocytes express a set 
of apical nutrient transporters. The HNF4a 7  
screen in intestinal cells only revealed the proton 
amino acid transporter PAT1 as a target. 
However, HNF4a binds to the Hnf1a promoter 
and vice versa, thereby extending the target 
genes for any of the two transcription factors 
(34). Previous studies have found tissue-specific 
interactions between HNF4a and HNF1a (16). 
Hnf4a mRNA can be transcribed from two 
alternate promoters, one of which is HNF1a 
dependent. In liver and kidney Hnf4a 
transcription is independent of HNF1a, while in 
islets a different promoter is used resulting in 
HNF1a dependence. In the intestine both 
promoters are used, resulting in an 
interdependence of Hnf1a and Hnf4a expression. 
In agreement with these tissue differences a 
different model has been suggested in kidney, in 
which expression of epithelial transporters is 
driven by HNF1a alone (13). However, in vivo, 
HNF1a could activate Hnf4a, thereby indirectly 
activating Slc6a19. Alternatively, expression 
levels in the kidney are somewhat lower due to 
the lower efficiency with which HNF1A 
activates the Slc6a19 promoter.  
SOX9 has been shown to be an 
important regulator of differentiation in various 
cell types, including cells of the small intestine 
(35,36), where it is integral part of the Wnt 
signalling pathway (37). In the crypt 
compartment it has been shown to act as a 
repressor cell differentiation, inhibiting the 
expression of genes involved in maturation, such 
as Cdx2, and Muc2 (37). In analogy to the results 
presented here for Slc6a19, reduced SOX9 
expression in villus cells could allow CDX2 
expression, which in turn could then be involved 
in the regulation of various other transcriptional 
regulators such as Cdx1, Hnf1a, and Hnf4a 
(38,39). In agreement with this model we found 
that CDX2 expression is higher in the crypt-
enriched fraction, thus suggesting that SOX9 is 
not controlling gene expression indirectly via 
CDX2. Instead, our results suggest that SOX9 
directly prevents the premature expression of 
genes involved nutrient absorption in 
undifferentiated intestinal crypt cells, despite the 
presence of positive regulators in this 
compartment. The inhibitory action of SOX9 is 
at least in part mediated by a specific SOX9 
binding site in the Slc6a19 promoter. In addition 
we found evidence for non-specific DNA 
binding or action as an inhibitory cofactor 
through protein-protein interactions. Upon 
down-regulation of Sox9 in differentiated 
enterocytes, transcription of genes involved in 
nutrient absorption is activated.  
This minimal model cannot explain the 
lack of epithelial nutrient transporter expression 
in hepatocytes, where HNF1a and HNF4a are 
abundant and SOX9 is missing. Kikuchi et al. 
(13) suggested that in the liver, specific CpG 
dinucleotides within promoters of transporter 
genes would be methylated. For Slc6a19 
differential methylation was observed at position 
-1080 upstream from the transcriptional start 
site. Given that the core promoter of Slc6a19 is 
less than 300bp long, it appears unlikely that the 
proposed methylation would directly affect the 
promoter recruitment of activators. Our bisulfite 
sequencing data, by contrast, demonstrate 
differential methylation at the proximal promoter 
where binding of transcription factors and RNA 
polymerase II occurs.  Intriguingly, the 
methylation pattern of the proximal B0AT1 
promoter changes rapidly, from fully methylated 
in the crypt to completely de-methylated in 
mature enterocytes. Due to the thermodynamic 
stability of CpG methylation, de-methylation can 
only occur by lack of re-methylation after 
mitosis or by a modified DNA excision repair 
mechanism (40,41).  Rapid de-methylation has 
nevertheless been demonstrated in neurons (42) 
and hormone-sensitive promoters (43). Stem 
cells in the crypt undergo three to four cell 
divisions before differentiation (44), thus de-
methylation could occur by both mechanisms. 
The complete methylation of the Slc6a19 
promoter observed in liver cells is in line with an 
absence of expression in this tissue. This 
suggests that de-methylation must occur before 
HNF1a or HNF4a can bind and activate 
transcription. 
Differential histone acetylation has been 
reported for the sucrose-isomaltase gene and 
promoter along the crypt-villus axis (32). Di-
acetylated histone H3 (lysine 9 and 14), which is 
associated with transcriptionally active genes, 
was found to be very low in the crypts, but much 
higher in the villus. Analysis of the ENCODE 
database (45) at the Slc6a19 promoter confirmed 
an active histone signature in the intestine and 
kidney (Fig. 9). Histone modification H3K4me3 
was highly enriched over the promoter, allowing 
binding of polymerase II. Histone modification 
H3K36me3 was present over all exons 
confirming that the gene was actively 
transcribed. These three elements were absent in 
other tissues including the liver, where HNF1a 
and HNF4a are highly expressed. This suggests 8  
that histone modification also should occur 
before transcription can be initiated. 
Our data suggest a model, whereby cell-
specific and tissue-specific regulation of B0AT1 
expression is mediated by a concurrent 
combination of three mechanisms: 1) different 
levels of activating and repressing transcription 
factors in crypt and villus cells; 2) reversible 
histone modifications and 3) reversible promoter 
methylation. Stem cells in the crypt undergo 4-5 
divisions during which differentiation occurs. 
During these divisions change of histone 
modification and removal of promoter 
methylation could occur. In addition SOX9 
could become diluted allowing the onset of 
B0AT1 expression, which gradually increases as 
cells move to the tip of the villus (Fig. 1).  
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Figure legends: 
 
Figure 1: Expression of B0AT1 in the intestine. 
Sections from the intestine of adult mice were stained with antibodies specific for mB0AT1 (green) 
(A). Probes corresponding to the sense and antisense strand of mB0AT1 cDNA were generated by in 
vitro transcription. The antisense probe was hybridized to mRNA in sections from small intestine (B). 
 
 
Figure 2:  HNF1a and HNF4a can activate the Slc6a19 promoter in vitro. 
HEK293 cells were co-transfected with vectors expressing Firefly luciferase downstream of the 
Slc6a19 promoter (A,B) or the Ace2 promoter (C), and with control vector expressing Renilla 
luciferase from a constitutive promoter. Firefly luciferase activity is depicted as % of control 
luminescence generated by Renilla luciferase. The Slc6a19 promoter deletion constructs are labeled 
with their 5’terminus position relative to the TSS and are depicted on the left panel, reporter gene 
activity is depicted in the right panel. Positions relative to the transcriptional start point are indicated. 
To analyse Slc6a19 transcriptional activation, HNF1a (A) or HNF4a (B) was co-expressed in the cells 
(open bars) and compared to the promoter construct only (black bars). Activation of the Ace2 
promoter was analysed after co-expression of HNF1a, HNF4a and SOX9. Significant increases of 
promoter activity due to co-transfection of HNF1 and HNF4a are indicated (* p<0.05; ** p<0.01). P 
values indicate the significance derived from three experiments, each with 3 separate transfections.  
 
 
Figure 3: Expression profile of Slc6a19, Lgr5 and Sox9 along the villus-crypt axis. 
Sections of inverted intestine were mounted onto a rod and sealed in a buffer containing tube. Cells 
were dislodged by slow rotation of the tube. The bathing solution was exchanged seven times in 
regular intervals generating fractions 1-7 (F1-F7). Expression levels of Slc6a19 (A), Lgr5 (B) and 
Sox9 (B) were determined by qPCR. The mean, upper and lower value of two experimental repeats 
are shown.    
 
Figure 4: SOX9 is a negative regulator of transcription. 
HEK293 cells were cotransfected with vectors expressing Firefly luciferase downstream of the 
Slc6a19 promoter and with control vector expressing Renilla luciferase from a constitutive promoter. 
Firefly luciferase activity is depicted as % of control luminescence generated by Renilla luciferase. To 
analyse transcriptional activation, cells were analysed without additional transcription factors (black 
bar), with HNF1a (open bar, A) or HNF4a (open bar B) or with HNF1a plus SOX9 (grey bar, A) or 
with HNF4a plus SOX9 (grey bar, B). Constructs are labeled with their 5’terminus relative to the 
TSS. Significant reduction of promoter activity due to SOX9 co-transfection are indicated (* p<0.05; 
** p<0.01). P values indicate the significance derived from three experiments, each with 3 separate 
transfections. 
 
Figure 5: Characterization of SOX9 action at the Slc6a19 promoter. 
HEK293 cells were co-transfected with vectors expressing Firefly luciferase downstream of the 
Slc6a19 wildtype promoter (open bars) or an Slc6a19 promoter with mutated SOX9 binding site 
(black bars). All constructs were expressed together with control vector expressing Renilla luciferase 
from a constitutive promoter. Firefly luciferase activity is depicted as % of control luminescence 
generated by Renilla luciferase. To analyse SOX9 action, the Slc6a19 reporter was co-expressed with 
the following transcription factors: (A) HNF1a, HNF1a plus SOX9, HNF1a plus SOX9(H65Y),   or 
(B) HNF4a, HNF4a plus SOX9, HNF4a plus SOX9(H65Y). Construct -473 (see Fig. 2) was used as 
base for all constructs. Significant reduction of promoter activity due to SOX9 co-transfection are 
indicated (* p<0.05; ** p<0.01). P values indicate the significance derived from three experiments, 
each with 3 separate transfections. 
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Figure 6. In vivo binding analysis of SOX9, HNF1a, and HNF4a at the proximal Slc6a19 
promoter. 
Chromatin immunoprecipitation was carried out using genomic DNA isolated from freshly scraped 
mucosa. Data are given in % relative to a quantitative PCR reaction on input DNA. Positions of 
primer sets along the Slc6a19 promoter are indicated. The mean signal ± SD of three independent 
experiments is shown. 
 
Figure 7: Analysis of histone modifications in the intestine and liver.   
Chromatin immunoprecipitation was carried out using genomic DNA isolated from enterocytes 
derived from fraction 2 (villus) and fraction 5 (crypt) and from genomic DNA isolated from liver 
tissue. Data are given in % relative to a real-time PCR reaction on input DNA. After cross-linking, 
antibodies specific for histone H3, variant H3K27ac and H3K4me3 were used to precipitate DNA 
fragments. Positions of primer sets along the Slc6a19 promoter are indicated. The mean signal ± SD 
of three independent experiments is shown.  
 
Figure 8: DNA methylation patterns of the B0AT1 promoter in different tissues. 
Bisulfite sequencing was used to determine methylated CpG dinucleotides. DNA was isolated from 
liver and fractionated enteric cells using fraction 1 (villus) or fraction 5 (crypt). CpG positions (closed 
circle methylated, open circle unmethylated) and transcription factor binding sites are indicated. TSS, 
transcriptional start site. The number of sequenced independent PCR products is indicated by the 
number of symbols. 
 
Figure 9: Histone modification and polymerase II binding to the Slc6a19 promoter 
The ENCODE database was used to extract the distribution of histone modifications H3K4me3, 
H3K36me3 and RNA polymerase II binding along the mouse Slc6a19 gene. The Slc6a19 gene shows 
active histone status and polymerase II binding in small intestine and kidney, but not in liver. 
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Table 1: Predicted Transcription factor binding sites in the Slc6a19 promoter. 
Transcription factors with robust expression in either crypt or villus were selected. GATA4 is listed 
because it has previously been indicated in enterocyte maturation, but does not have a predicted 
binding site. A matrix number of 1.00 indicates an exact match of the binding site consensus 
sequence. Revised location indicates results from mutagenesis data. A qualitative indicator is 
provided for the effect on transcription. The ratio of mRNA abundance along the villus-crypt axis was 
determined by microarray analysis. * Unless stated otherwise the effect of co-expression of the listed 
transcription factor with the promoter construct is shown. 
TFs Position Strand Matrix Revised 
location 
Effect on 
Transcription* 
Ratio 
Villus/Crypt  
ATF4 -1212/-1204 - 0.996  0 0.90 
Cdx2 -36/-18 - 0.928  0 0.52 
Cdx2 -1212/-1194 - 0.870  0 0.52 
Cdx2 -1833/-1815 + 0.867  0 0.52 
Creb3l3 -89/-69 + 0.954  0  8.8 
Egr1 -167/-151 + 0.890  0 0.11 
Egr1 -2112/-2096 + 0.863  0 0.11 
FoxA2 -305/-289 - 0.991  0 0.32 
FoxA2 -835/-819 - 0.995  0 0.32 
GATA4 - - -  0 0.91 
HNF1a – 
BS1 
-126/-110 - 0.817 -126/-110 ++ 0.96 
HNF1a – 
BS2  
-153/-137 + 0.891  0 0.96 
HNF4a – 
BS1 
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